본문으로 건너뛰기
← 뒤로

Three years of chemotherapy tolerance with concurrent Ayurvedic treatment in a metastatic lung adenocarcinoma: A case report.

Journal of Ayurveda and integrative medicine 2026 Vol.17(2) p. 101325

Nimbalkar RG, Marne PA, Kulkarni VM, Baheti AM, Pawar AT, Tagalpallewar AA, Nimbalkar MR

📝 환자 설명용 한 줄

Lung adenocarcinoma, a prevalent form of non-small cell lung cancer, presents significant challenges due to its advanced stage at diagnosis and heterogeneity.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Nimbalkar RG, Marne PA, et al. (2026). Three years of chemotherapy tolerance with concurrent Ayurvedic treatment in a metastatic lung adenocarcinoma: A case report.. Journal of Ayurveda and integrative medicine, 17(2), 101325. https://doi.org/10.1016/j.jaim.2026.101325
MLA Nimbalkar RG, et al.. "Three years of chemotherapy tolerance with concurrent Ayurvedic treatment in a metastatic lung adenocarcinoma: A case report.." Journal of Ayurveda and integrative medicine, vol. 17, no. 2, 2026, pp. 101325.
PMID 41825247

Abstract

Lung adenocarcinoma, a prevalent form of non-small cell lung cancer, presents significant challenges due to its advanced stage at diagnosis and heterogeneity. This case report details the therapeutic journey of a 61-year-old female patient diagnosed with metastatic lung adenocarcinoma, managed through an integrative approach combining chemotherapy and Ayurvedic treatment. Conventional therapy consisted of carboplatin, pemetrexed, and geftinib, targeting both primary and metastatic sites. Concurrent Ayurvedic treatment was introduced to alleviate chemotherapy-related side effects and enhance the patient's quality of life. Over a 36 months period, the patient demonstrated minimal side effects and a near-complete regression of the primary lung lesions. This case highlights the potential of Ayurvedic medicine as an adjunct to chemotherapy, offering improvements in symptom management and overall patient well-being, without obstructing the chemotherapy efficacy.